Reumatoloxía
Servicio
Boston University School of Medicine
Boston, Estados UnidosPublicacións en colaboración con investigadores/as de Boston University School of Medicine (30)
2024
-
Can gait patterns be explained by joint structure in people with and without radiographic knee osteoarthritis? Data from the IMI-APPROACH cohort
Skeletal Radiology, Vol. 53, Núm. 11, pp. 2409-2416
2023
-
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance
Arthritis Care and Research, Vol. 75, Núm. 1, pp. 53-60
-
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Annals of the rheumatic diseases, Vol. 82, Núm. 5, pp. 698-709
-
Exploring the differences between radiographic joint space width and MRI cartilage thickness changes using data from the IMI-APPROACH cohort
Skeletal Radiology, Vol. 52, Núm. 7, pp. 1339-1348
-
Machine-learning predicted and actual 2-year structural progression in the IMI-APPROACH cohort
Quantitative Imaging in Medicine and Surgery, Vol. 13, Núm. 5, pp. 3298-3306
-
Quantitative CT of the knee in the IMI-APPROACH osteoarthritis cohort: Association of bone mineral density with radiographic disease severity, meniscal coverage and meniscal extrusion
Bone, Vol. 168
-
Test–retest precision and longitudinal cartilage thickness loss in the IMI-APPROACH cohort
Osteoarthritis and Cartilage, Vol. 31, Núm. 2, pp. 238-248
2022
-
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
ACR Open Rheumatology, Vol. 4, Núm. 11, pp. 948-953
-
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Annals of the rheumatic diseases, Vol. 81, Núm. 7, pp. 970-978
-
Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry
ACR Open Rheumatology, Vol. 4, Núm. 10, pp. 872-882
-
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
The Lancet Rheumatology, Vol. 4, Núm. 9, pp. e603-e613
-
Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
RMD Open, Vol. 8, Núm. 2
-
Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera
Annals of the Rheumatic Diseases
-
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: Results from the COVID-19 Global Rheumatology Alliance provider registry
RMD Open, Vol. 8, Núm. 1
-
Structural tissue damage and 24-month progression of semi-quantitative MRI biomarkers of knee osteoarthritis in the IMI-APPROACH cohort
BMC Musculoskeletal Disorders, Vol. 23, Núm. 1
2021
-
Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19
JAMA Network Open
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Annals of the Rheumatic Diseases, Vol. 80, Núm. 9, pp. 1137-1146
-
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases
The Lancet Rheumatology, Vol. 3, Núm. 10, pp. e707-e714
-
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
The Lancet Rheumatology, Vol. 3, Núm. 12, pp. e855-e864
2020
-
Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810